Table 2 Adverse events reported in > 5%... | American Society of Hematology

Table 2

Adverse events reported in > 5% of patients treated with a single dose of rozrolimupab

Adverse events	Adverse event grading
Adverse events	Mild	Moderate	Severe	All
Headache	13.1	4.9	1.6	19.7
Pyrexia	9.8	3.3	0.0	13.1
Petechiae	8.2	0.0	1.6	9.8
Hematoma	9.8	0.0	0.0	9.8
Low platelet counts	1.6	6.6	1.6	9.8
Chills	9.8	0.0	0.0	9.8
Fatigue	6.6	1.6	0.0	8.2
Increased D-dimer	4.9	3.3	0.0	8.2
Decreased hemoglobin	3.3	3.3	0.0	6.6
Thrombocytopenia	0.0	1.6	4.9	6.6
Hematuria	4.9	1.6	0.0	6.6
Asthenia	4.9	1.6	0.0	6.6
Anemia	3.3	3.3	0.0	6.6
Dizziness	6.6	0.0	0.0	6.6

Adverse events	Adverse event grading
Adverse events	Mild	Moderate	Severe	All
Headache	13.1	4.9	1.6	19.7
Pyrexia	9.8	3.3	0.0	13.1
Petechiae	8.2	0.0	1.6	9.8
Hematoma	9.8	0.0	0.0	9.8
Low platelet counts	1.6	6.6	1.6	9.8
Chills	9.8	0.0	0.0	9.8
Fatigue	6.6	1.6	0.0	8.2
Increased D-dimer	4.9	3.3	0.0	8.2
Decreased hemoglobin	3.3	3.3	0.0	6.6
Thrombocytopenia	0.0	1.6	4.9	6.6
Hematuria	4.9	1.6	0.0	6.6
Asthenia	4.9	1.6	0.0	6.6
Anemia	3.3	3.3	0.0	6.6
Dizziness	6.6	0.0	0.0	6.6

Values are percentages.